- ►chestpubs.org WH Geerts, GF Pineo, JA Heit, D Bergqvist, … - Chest, 2004 - chestjournal.chestpubs.org This article discusses the prevention of venous thromboembolism (VTE) and is
part of the Seventh American College of Chest Physicians Conference on
Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Grade 1 ... Cited by 3329 - Related articles - BL Direct - All 58 versions
- ►va.gov [PDF] BI Eriksson, KA Bauer, MR Lassen, AGG … - The New England journal of medicine, 2001 - nejm.highwire.org 1298 · N Engl J Med, Vol. 345, No. 18 · November 1, 2001 · www.nejm.org ...
FONDAPARINUX COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS
THROMBOEMBOLISM AFTER HIP-FRACTURE SURGERY ... B ENGT I. E RIKSSON , MD, K ... Cited by 362 - Related articles - BL Direct - All 9 versions
CB Phillips, JA Barrett, E Losina, NN … - The Journal of Bone and Joint Surgery, 2003 - JBJS In support of their research or preparation of this manuscript, one or more of
the authors received National Institutes of Health Grants P60 AR36308, P60
AR47782, and K24 AR02123 and a Clinical Science Grant from the Arthritis ... Cited by 147 - Related articles - BL Direct - All 5 versions
- ►tums.ac.ir [PDF] BI Eriksson, LC Borris, RJ Friedman, S Haas … - New England Journal of Medicine, 2008 - content.nejm.org From Sahlgrenska University Hospital– Östra, Gothenburg, Sweden (BIE); Aar-
husUniversityHospital,Aarhus,Denmark (LCB); Medical University of South Car-
olina, Charleston (RJF); Institute of Ex- perimental Oncology and Therapy ... Cited by 137 - Related articles - All 14 versions
BI Eriksson, OE Dahl, N Rosencher, AA Kurth, … - The Lancet, 2007 - Elsevier In this double-blind study, we randomised 3494 patients undergoing total hip
replacement to treatment for 28–35 days with dabigatran etexilate 220 mg
(n=1157) or 150 mg (1174) once daily, starting with a half-dose 1–4 h ... Cited by 124 - Related articles - All 33 versions
BI Eriksson, MR Lassen - Archives of Internal Medicine, 2003 - Am Med Assoc Results The primary efficacy outcome was assessed in 428 patients. Fondaparinux
reduced the incidence of VTE compared with placebo from 35.0% (77/220) to 1.4%
(3/208), with a relative reduction in risk of 95.9% (95% confidence ... Cited by 116 - Related articles - BL Direct - All 4 versions
SR Kahn, JS Ginsberg - Archives of Internal Medicine, 2004 - Am Med Assoc The postthrombotic syndrome (PTS) is a frequent complication of deep venous
thrombosis (DVT). Clinically, PTS is characterized by chronic, persistent pain,
swelling, and other signs in the affected limb. Rarely, ulcers may develop. ... Cited by 101 - Related articles - BL Direct - All 8 versions
G Agnelli, D Bergqvist, AT Cohen, AS Gallus, … - British Journal of Surgery, 2005 - ingentaconnect.com Page 1. Randomized trial Randomized clinical trial of postoperative fondaparinux
versus perioperative dalteparin for prevention of venous ... Cited by 83 - Related articles - All 5 versions
- ►gu.se [PDF] AK Kakkar, B Brenner, OE Dahl, BI Eriksson, P … - The Lancet, 2008 - Elsevier 2509 patients scheduled to undergo elective total hip arthroplasty were randomly
assigned, stratified according to centre, with a computer-generated
randomisation code, to receive oral rivaroxaban 10 mg once daily for ... Cited by 79 - Related articles - All 44 versions
SR Kahn, JS Ginsberg - Blood reviews, 2002 - Elsevier The post-thrombotic syndrome (PTS) is a long-term complication of deep venous
thrombosis (DVT) that is characterized by chronic, persistent pain, swelling and
other signs in the affected limb. PTS is common, burdensome and costly. It ... Cited by 69 - Related articles - BL Direct - All 12 versions
